Mylan Laboratories, Inc. (NASDAQ: MYL) rated to Buy with price target $66 by Deutsche Bank
Deutsche Bank rated Mylan
Laboratories, Inc. (NASDAQ: MYL) to Buy with price target $66.
Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan?s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA?s Central & Eastern Europe (CEE) generics businesses.
is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank
. This division is one of the largest global asset managers.